Scottish tech company Chemify has received $1.6 million from the Gates Foundation to continue the discovery of small molecules for tuberculosis (TB). Building on a successful collaboration with Lgenia, the expanded project will leverage Chemify’s automated platform to design and synthesise new drug leads, aiming to address one of the world’s most… Read More
A new study by the Massachusetts Institute of Technology (MIT) has revealed new targets for a tuberculosis (TB) vaccine. A large-scale screen of tuberculosis proteins highlighted several possible antigens that could be developed as a new vaccine for TB, the world’s deadliest infectious disease. A team of… Read More
Pharmaceutical companies GSK and ViiV Healthcare have invested £6 million ($8 million) in the Global Fund to Fight AIDS, Tuberculosis and Malaria. The investment will strengthen community-led responses to HIV, tuberculosis (TB) and malaria in lower income countries. The commitment will also be matched by the Gates… Read More
For the first time, a controlled human infection model for tuberculosis (TB) has been developed and could help with the future development of TB vaccines. Researchers from the University of Oxford developed the infection model, which replicates how TB enters the body by infecting people… Read More
The vaccines currently in late-stage development hold promise in tackling the disease burden of tuberculosis (TB), says data and analytics company GlobalData on World Tuberculosis Day 2024. World TB Day is marked annually on 24 March, the anniversary of the discovery of the causative mycobacterium by… Read More
Roche Diagnostics and ABL Diagnostics have launched a distribution partnership which will see Roche supplying ABLD products to South African laboratories. Roche now has exclusive rights to distribute products, including the ABL DeepChek assays to laboratories implementing microbiology applications. These applications include HIV, Tuberculosis, Cytomegalovirus, Viral… Read More
A first-in-class investigational antitubercular agent has shown early bactericidal activity with a low, once-daily oral dose after 14 days of treatment. The Phase IIa study evaluated GSK’s GSK3036656 in participants with drug-susceptible pulmonary tuberculosis. The company hopes GSK3036656 could be a component of simpler treatment regimens in… Read More
New research has furthered our understanding of the immune-related factors that drive infection and disease, which will be necessary for an effective tuberculosis (TB) vaccine to be developed. Researchers from the University of Oxford investigated whether previously identified correlates of protection associated with risk of full-blown TB disease could also… Read More
The Comprehensive Resistance Prediction for Tuberculosis International Consortium (CRyPTIC) research project has reportedly collected the largest ever global dataset of clinical M. tuberculosis samples from across the world consisting of 15,211 samples from 27 countries on five continents. Using a new quantitative test for drug resistance and… Read More
